Effective antibiotics
from the first try even
for drug-resistant infections

AtbFinder addresses the most important question: can antibiotics at concentration that actually occurs at the site of infection eliminate the infection.

Why Patients
Choose AtbFinder®

100%

Clinical response rate when previous antibiotic regimen failed.

100%

clinical response rate in the most complex infections:

Antibiotic-resistant

Chronic or recurrent

Immunocompromised patients

Polymicrobial and mixed bacterial–fungal

100%

eradication of chronic, recurrent and relapsing infections

80% eradicated after the first AtbFinder-guided antibiotic selection

100% eradicated after the subsequent AtbFinder-guided treatment

Progression to ICU or death

Faster improvement

Shorter hospital stays

AtbFinder enables selection of effective antibiotics for complex, chronic, and antibiotic-resistant infections, supporting their eradication.

Feature

Personalized for each
patient's infection

AtbFinder is the only test that uses actual disease-adjusted, tissue-level antibiotic concentrations, matching how drugs behave at the site of infection: bladder, lungs, blood, skin, or wounds

90-180

Antibiotics per patient

Only AtbFinder evaluates patient-specific antibiotic combinations

AtbFinder selects antibiotics mirroring EACH patient's infection environment

AtbFinder selects antibiotics that target not only the "Primary Pathogen" but also microorganisms that support pathogen survival. Thus disrupting the entire microbial community

AtbFinder selects antibiotics that work in real clinical conditions - even for antibiotic resistant pathogens

How get

AtbFinder is an all-in-one proprietary laboratory-developed test which is processed in our first-in-class CLIA certified laboratory facility.

Sample collection

Shipment to Lab

AtbFinder testing

Results in 6-20 hours*

References

Tetz G, Tetz V. Evaluation of a New Culture-Based AtbFinder Test-System Employing a Novel Nutrient Medium for the Selection of Optimal Antibiotics for Critically Ill Patients with Polymicrobial Infections within 4 h. Microorganisms. 2021 May 4;9(5):990. doi: 10.3390/microorganisms9050990.

Tetz G, Kardava K, Vecherkovskaya M, Hahn A, Tsifansky M, Koumbourlis A, Tetz V. AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis. J Clin Microbiol. 2023 Jan 26;61(1):e0155822. doi: 10.1128/jcm.01558-22.

Tetz GV, Kardava KM, Vecherkovskaya MF, Tsifansky MD, Tetz VV. Treatment of chronic relapsing urinary tract infection with antibiotics selected by AtbFinder. Urol Case Rep. 2022 Dec 28;46:102312. doi: 10.1016/j.eucr.2022.102312. 2026 ASCO Annual Meeting New Paradigm for Antibiotic Selection in Hard-to-Treat Drug-Resistant Infections Following HSCT

AUA 2026

AtbFinder: A Novel Diagnostic Test That Improves Antibiotic Selection and Clinical Outcomes in UTI-Associated Cognitive Decline and Delirium in Patients with Neurodegenerative Disorders

SIDP & MAD-ID Annual Meeting

Microbial Cell Memory in Biofilms: A New Frontier for Effective Antibiotic Selection in Hard-to-Treat Drug-Resistant Infections

Effective antibiotics from the first try even for drug-resistant infections

Effective antibiotics
from the first try even
for drug-resistant infections